Role of RUNX2 in Oral Squamous Cell Carcinoma (OSCC): A Systematic Scoping Review

Table 4

List of studies included.

Authors (Reference)	Date of publication	Study population	Key points
Ma et al. [42]	March 2022	OSCC patients	(i) Inhibition of RUNX2 reduced the malignant progression of oral squamous cell carcinoma CAL-27 and TSCCA
			(ii) Increased expression of RUNX2 reverses the cancer suppressive effect of miR-23a-3p
			(iii) miR-23a-3p inhibits the PTEN/PI3K/Akt signaling pathway through RUNX2
Zhang et al. [28]	February 2022	OSCC patients	(i) GDF10 interacts with RUNX2 to promote fibroblast activation which improve OSCC tumor cells growth and migration by activating the TGFβRI/Smad3/ERK pathway
Wang et al. [43]	April 2021	OSCC patients	(i) Positive correlation between MRE11, CXCR4 and RUNX2 in oral cancer tissues
			(ii) MRE11 promotes EMT and metastasis through RUNX2, CXCR4, AKT, and FOXA2
Khanal et al. [44]	December 2020	Head and neck cancer cell lines	(i) Decreased expression of RUNX2 was observed in human papilloma virus positive head and neck cancer cells while it was not the target of epigenetic regulation
Chang et al. [45]	January 2017	Specimens from HNSCC patients	(i) Deranged RUNX2 expression increased PTHLH expression and promoted proliferation potential
Chang et al. [46]	December 2016	Head and neck squamous cell carcinoma cell lines	(i) RUNX2 has a prometastatic action in HNSCC and causally correlates with the metastatic potential of HNSCC
			(ii) Downregulation of tumor suppressor microRNA, miRNA-376c-3p promotes invasive and migratory abilities of HNSCC by upregulating RUNX2/INHBA axis
Quan et al. [47]	June 2012	OSCC cell lines	(i) RUNX2 levels were not altered in invasive phenotype of OSCC cells